Discourage Using PPIs With New Hep C Med Epclusa

September 2016

Please see the October 2016 FDA advisory about the risk of Hepatitis B reactivation in some patients being treated for Hepatitis C....

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Quality Measures Ensure Close Follow-up to Help Reduce Readmissions and Improve Star Ratings
Pneumonia Treat Most HAP or VAP Patients With 7 Days of Antibiotics
Hematology Oncology Don't Automatically Start Empiric Vancomycin for Febrile Neutropenia
Heart Failure Avoid Restarting Risky Meds at Discharge in Heart Failure Patients
Constipation Remove Docusate From Hospital Order Sets Due to Minimal Benefit
HIV AIDS Check Creatinine Clearance When Using Tenofovir
Epinephrine Make Epinephrine Kits to Treat Anaphylaxis Patients In House
Angina Save Ranolazine (Ranexa) for Patients Who Can't Tolerate Other Angina Meds
Ophthalmology Switch to Preservative-Free Artificial Tears When Using Over Four Times Daily
Opioids Use Prescription Drug Monitoring Programs to Help Prevent Opioid Misuse
Hepatitis C Discourage Using PPIs With New Hep C Med Epclusa